Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01430975 · ClinicalTrials.gov registry record
Prospective Evaluation of Strontium in Patients After CardioGen-82 PET MPI Scanning at Two Clinical Sites
A clinical trial of Radiation Exposure, sponsored by Bracco Diagnostics.
- Completed
- Registry status
- 72
- Enrollment target
- 1
- Study location
NCT01430975: Completed study of Radiation Exposure, sponsored by Bracco Diagnostics.
NCT01430975 is a study of Radiation Exposure that has completed, run by Bracco Diagnostics. The registered enrollment target is 72 participants, above the 40-participant average among 7 other Radiation Exposure trials with a reported enrollment target (80% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01430975, a study of Radiation Exposure, has completed, sponsored by Bracco Diagnostics.
- COMPLETED
- Registry status
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is to be performed at two clinical sites where patients received CardioGen-82 during the time period January to June, 2011 and where patients were scanned chronologically near to the index patients (2 days before or after). Of these, it is planned that at least 30 patients will be entered in this trial. Index patient is the term applied to individuals who had radiation spectra indicative of Sr-82 and Sr-85 detected by hand-held survey meters.
Primary Outcome
To determine radiation exposure from Sr-82 and/or Sr-85 in patients administered CardioGen-82® for PET MPI at the two sites reporting Sr-82/Sr-85 breakthrough
Conditions Studied
Interventions
- DRUG CardioGen-82
Study Locations (1)
New Jersey
- Bracco Diagnostics, Inc. - Princeton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2011-09 |
| Est. Completion | 2012-03 |
What the finished NCT01430975 record still lists
NCT01430975 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 72 participants, a relatively small participant target, above the 40-participant average among 7 other Radiation Exposure trials with a reported enrollment target (80% higher).
The record links to 1 condition, with Radiation Exposure appearing as the primary indexed condition, and to 1 intervention - of which CardioGen-82 is the first listed.
NCT01430975 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT01430975 about?
NCT01430975 is a clinical study titled "Prospective Evaluation of Strontium in Patients After CardioGen-82 PET MPI Scanning at Two Clinical Sites". This study is to be performed at two clinical sites where patients received CardioGen-82 during the time period January to June, 2011 and where patients were scanned chronologically near to the index patients (2 days before or after). Of these, it is planned that at least 30 patients will be entered...
What is the current status of trial NCT01430975?
This trial is currently completed. The enrollment target is 72 participants. The study started on 2011-09. Estimated completion is 2012-03.
What conditions does trial NCT01430975 study?
This clinical trial studies the following conditions: Radiation Exposure.
What interventions are being tested in trial NCT01430975?
The interventions under investigation include: CardioGen-82 (DRUG).
Who is sponsoring clinical trial NCT01430975?
This trial is sponsored by Bracco Diagnostics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01430975 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Radiation Exposure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment
RECRUITING · NA
-
MRI Biomarkers for Radiation-Induced Neurocognitive Decline Following SRS of Newly Diagnosed Brain Mets
RECRUITING
-
Fluoroscopy Radiation Reduction During Sacral Neuromodulation Lead Placement
RECRUITING · NA
-
Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Reduce Radiation Exposure in Fluoroscopic Interventions Evaluation
COMPLETED · NA
-
A Prospective Study of Radiation Exposure to Surgeons
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia